This podcast explores the latest advancements in treating ovarian and endometrial tumors, with a particular emphasis on ovarian cancer and the role of PARP inhibitors in first-line maintenance therapy. It underscores the importance of various factors in treatment selection, such as BRCA mutation status, homologous recombination deficiency (HRD), chemotherapy response (evaluated through tools like Kelim and CRS scores), residual disease post-surgery, patient comorbidities, and the toxicity profiles of different PARP inhibitors, including Olaparib and Niraparib. Through clinical case studies, the podcast highlights the complexities of choosing the right treatment and the necessity for personalized care, stressing the vital role of genetic testing and a multidisciplinary approach.
